Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ioannis Parodis

Showing results (1-10 of 188) with videos related to

Pageof 19
Sort By:
The Lancet. Rheumatology|December 20, 2024
Promise and challenges of mesenchymal stromal cell therapy in severe SLEIoannis Parodis
Arthritis & Rheumatology (Hoboken, N.J.)|February 5, 2026
When blood proteins reveal what transcripts miss: immune cell priming and the road to prognostic biomarkers in lupusIoannis Parodis
Lupus Science & Medicine|April 10, 2024
Enhancing lupus outcomes by means of biology beyond overt clinical features, exemplified in an in-depth investigation of the effects of circadian rhythm disruptionIoannis Parodis
Rheumatology (Oxford, England)|April 15, 2026
Revisiting lupus low disease activity: validation matters, but vindication is imperativeIoannis Parodis
The Lancet. Rheumatology|January 22, 2024
Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosusIoannis Parodis
Annals of the Rheumatic Diseases|May 12, 2019
How to use the Lupus Low Disease Activity State (LLDAS) in clinical trialsIoannis Parodis, Mandana Nikpour
Autoimmunity Reviews|September 11, 2022
Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literatureAlvaro Gomez, Ioannis Parodis
Frontiers in Medicine|July 17, 2023
Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibitionDionysis Nikolopoulos, Ioannis Parodis
International Journal of Molecular Sciences|September 28, 2024
Immune Mechanisms and Biomarkers in Systemic Lupus ErythematosusIoannis Parodis, Christopher Sjöwall
Journal of Clinical Medicine|November 26, 2022
Clinical Heterogeneity, Unmet Needs and Long-Term Outcomes in Patients with Systemic Lupus ErythematosusChristopher Sjöwall, Ioannis Parodis
Pageof 19

Showing results (1-10 of 188) with videos related to

Sort By:
Pageof 19
The Lancet. Rheumatology|December 20, 2024
Promise and challenges of mesenchymal stromal cell therapy in severe SLEIoannis Parodis
Arthritis & Rheumatology (Hoboken, N.J.)|February 5, 2026
When blood proteins reveal what transcripts miss: immune cell priming and the road to prognostic biomarkers in lupusIoannis Parodis
Lupus Science & Medicine|April 10, 2024
Enhancing lupus outcomes by means of biology beyond overt clinical features, exemplified in an in-depth investigation of the effects of circadian rhythm disruptionIoannis Parodis
Rheumatology (Oxford, England)|April 15, 2026
Revisiting lupus low disease activity: validation matters, but vindication is imperativeIoannis Parodis
The Lancet. Rheumatology|January 22, 2024
Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosusIoannis Parodis
Annals of the Rheumatic Diseases|May 12, 2019
How to use the Lupus Low Disease Activity State (LLDAS) in clinical trialsIoannis Parodis, Mandana Nikpour
Autoimmunity Reviews|September 11, 2022
Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literatureAlvaro Gomez, Ioannis Parodis
Frontiers in Medicine|July 17, 2023
Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibitionDionysis Nikolopoulos, Ioannis Parodis
International Journal of Molecular Sciences|September 28, 2024
Immune Mechanisms and Biomarkers in Systemic Lupus ErythematosusIoannis Parodis, Christopher Sjöwall
Journal of Clinical Medicine|November 26, 2022
Clinical Heterogeneity, Unmet Needs and Long-Term Outcomes in Patients with Systemic Lupus ErythematosusChristopher Sjöwall, Ioannis Parodis
Pageof 19